anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A plant based agent contains a natural symbiosis of the following microorganism cultures bacterium xylinum, Bacterium gluconicum, Saccheromyces ludwigii, Saccheromyces apiculatus types, Schizosaccheromyces pombe, Torula spp, Acetobacter ketogerum, Pichia fermentans and other yeasts. in water which has been brewed up with dry sugar cane juice and green tea. USE/ADVANTAGE - For regenerating skin of fresh burn wounds, for cleaning dirty skin and for treating varicose veins by topical application (claimed). The liq. can be used when ice cold, to impregnate cloths which are then placed on the wound. For cleaning skin, the liq. is left in an aerated room until a skin forms in the surface of the liquid. This microorganism skin is removed and placed and thepatients dirty skin, left for a few minutes and then washed off. In the treatment of varicose veins, the skin surface is alternately rinsed with ice cold water and a 0.5-1.5 cm thick microorganism layer placed on it. The use of dried sugar cane juice is better than the use of refined sugar, which contains no proteins or minerals. Green tea is used rather than black tea, which is not tolerated by everyone
Triple-negative breast cancer (TNBC) exhibits heightened aggressiveness compared with other breast cancer (BC) subtypes, with earlier relapse, a higher risk of distant metastasis, and a worse prognosis. Transcription factors play a pivotal role in various cancers. Here, we found that factor forkhead box M1 (FOXM1) expression was significantly higher in TNBC than in other BC subtypes and normal tissues. Combining the findings of Gene Ontology (GO) enrichment analysis and a series of experiments, we found that knockdown of the FOXM1 gene attenuated the ability of TNBC cells to proliferate and metastasize both in vivo and in vitro. In addition, Spearman's test showed that FOXM1 significantly correlated with glycolysis-related genes, especially centromere protein A (CENPA) in datasets (GSE76250, GSE76124, GSE206912, and GSE103091). The effect of silencing FOXM1 on the inhibition of CENPA expression, TNBC proliferation, migration, and glycolysis could be recovered by overexpression of CENPA. According to MeRIP, the level of m6A modification on FOMX1 decreased in cells treated with cycloleucine (a m6A inhibitor) compared with that in the control group. The increase in FOXM1 expression caused by YTHDC1 overexpression could be reversed by the m6A inhibitor, which indicated that YTHDC1 enhanced FOXM1 expression depending on m6A modification. Therefore, we concluded that the YTHDC1-m6A modification/FOXM1/CENPA axis plays an important role in TNBC progression and glycolysis.
Patients in this group will undergo lymphaticovenous anastomosis at one or more locations on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. Incisions will be made at the sites where lymphatic vessels are obstructed, ensuring no harm to the viable part of the lympahtic system. The locations will be determined prior to the surgery using ICG lymphography. The LVA(s) will be made in the subdermal plane with the aid of a surgical microscope. Generally, 1 to 4 LVAs are made. The LVA(s) is made using a surgical microscope and the operation will take approximately 60 to 90 minutes.
MDS patients with Intermediate, High, or Very-High R-IPSS risk will be enrolled. Allogeneic stem cell transplantation with regulatory and conventional T cell adoptive immunotherapy will be proposed to eligible High and Very-High risk MDS patients. Intermediate risk MDS patients will be assessed for risk modification every six months and moved to transplant in case of increased risk. Intermediate risk MDS patients will be also evaluated for the presence of molecular alterations (TP53, ASXL1, RUNX1). Overall survival of the entire cohort will be assessed as primary endpoint. Incidence of Treatment Related Mortality, acute Graft versus Host Disease, chronic Graft versus Host Disease, Relapse will be also assessed.
Participants in the medication group would take 150-mg pregabalin capsules orally twice daily (total daily dose, 300 mg) for 4 weeks. The follow-up period is 3 months.
Tocilizumab will be proposed to eligible patients as an emergency treatment, in addition to the standard high-dose steroid treatment. Each patient will receive the reference treatment, i.e. one pulse of high dose intravenous methylprednisolone per day during 3 days, followed by 1 mg/kg/day oral prednisone, and low dose aspirin. Depending on the randomization, each patient will receive the reference treatment only, or will received in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week), the first tocilizumab injection being delivered on the same day than the first steroid IV pulse. Study visits will take place at 4, 8 and 13 weeks. The primary endpoint will be the ocular improvement at W8, defined as an increase of at least two lines of visual acuity on the ETRS chart. For each patient, the duration of participation will by of 3 months. The study duration is expected to be 15 months.
Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. Participants in CM+TAU will receive reinforcement for submitting urine samples that test negative for recent alcohol use.
Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last study intervention administration at Day 232, and the pentavalent vaccine (DTPw-HepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.
In single-dose studies, benazepril lowered blood pressure within 1 hour, with peak reductions achieved 2 to 4 hours after dosing. The antihypertensive effect of a single dose persisted for 24 hours. In multiple-dose studies, once-daily doses of 20 mg to 80 mg decreased seated pressure (systolic/diastolic) 24 hours after dosing by about 6-12/4-7 mmHg. The reductions at trough are about 50% of those seen at peak.

Four dose-response studies of benazepril monotherapy using once-daily dosing were conducted in 470 mild-to-moderate hypertensive patients not using diuretics. The minimal effective once-daily dose of benazepril was 10 mg; further falls in blood pressure, especially at morning trough, were seen with higher doses in the studied dosing range (10 mg to 80 mg). In studies comparing the same daily dose of benazepril given as a single morning dose or as a twice-daily dose, blood pressure reductions at the time of morning trough blood levels were greater with the divided regimen.

The antihypertensive effects of benazepril were not appreciably different in patients receiving high- or low-sodium diets.
1,186,624. Extraction of Adonis vernalis L. SOLCO BASEL A.G. 22 Sept., 1967 [23 Sept., 1966]; No. 43350/67. Heading A5B. A cardioactive glycoside or a cardioactive glycoside-containing material is prepared by extracting leaves of Adonis vernalis L. with water or with water containing a water-miscible alcohol e.g. ethanol, separating the extract and removing solvent therefrom, extracting the residue with a water-miscible alcohol or ketone e.g. ethanol or acetone, removing solvent from the. extract, extracting said extract with a water-miscible ketone if a water-miscible alcohol was used in the preceding extraction step or vice versa, removing solvent from the resulting extract, dissolving the residue in an aqueous medium, successively extracting the resulting aqueous solution with a plurality of mixtures of chloroform or trichloroethylene and an alkanol having up to 4 carbon atoms e.g. ethanol or butanol, said mixtures having volume ratios in the range 9:1 to 2:1, chromatographically separating the extract or extracts obtained at volume ratios within the range 8:1 to 3:1, eluting the chromatographically separated constituents of the extract or extracts and evaporating said eluates to dryness. The leaves may be extracted in a nitrogen atmosphere at a temperature of not more than 100C. and the solvent may be removed from the separated extract by concentrating the resultant solution in vacuo to obtain a residue. The chromatographic procedure may be carried out on a carrier containing silicates, e.g. kieselguhr, diatomaceous earth or sea sand, by using a water-saturated butanol/toluene mixture of a ratio 1:1.
The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
<P>PROBLEM TO BE SOLVED: To provide an external preparation which is used for skin and improves a skin symptom, to provide a method for improving a skin symptom, to provide a method for diagnosing a skin symptom, and to provide a method for screening a galectin-7 expression-promoting substance effective for improving a skin symptom.  <P>SOLUTION: This external preparation for the skin contains an ingredient for increasing the content of galectin-7 in the skin, as an active ingredient. The galectin-7 itself, and a mixture of the galectin-7 with a galectin-7 expression-promoting substance having an action for increasing the expression of the galectin-7 in skin by contact with the skin are especially used. The external preparation for skin is coated on the skin to improve the skin symptom. The content of the galactin-7 in the skin is measured to diagnose the extent of the skin symptom. In addition, the content of the galectin-7 after the contact of a selection candidate substance with the skin is compared with the content of the galectin-7 in the skin before the contact to judge whether the increase in the content of the galectin-7 is significant or not.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
E74-like factor 3 (ELF3) is an important member of the E-twenty-six (ETS) transcription factor family. ELF3 is expressed in various types of cells and regulates a variety of biological behaviors, such as cell proliferation, differentiation, apoptosis, migration, and invasion, by binding to DNA to regulate the expression of other genes. In recent years, studies have shown that ELF3 plays an important role in the occurrence and development of many tumors and inflammation and immune related diseases. ELF3 has different functions and expression patterns in different tumors; it can function as a tumor suppressor gene or an oncogene, highlighting its dual effects of tumor promotion and inhibition. ELF3 also affects the levels of tumor immunity-related cytokines and is involved in the regulation and expression of multiple signaling pathways. In tumor therapy, ELF3 is a complex and multifunctional gene and has become a key focus of targeted treatment research. An in-depth study of the biological function of ELF3 can help to elucidate its role in biological processes and provide ideas and a basis for the development and clinical application of ELF3-related therapeutic methods. This review introduces the structure and physiological and cellular functions of the ELF3 gene, summarizes the mechanisms of action of ELF3 in different types of malignant tumors and its role in immune regulation, inflammation, etc., and discusses treatment methods for ELF3-related diseases, providing significant reference value for scholars studying the ELF3 gene and related diseases.
In the early phase, severe burns induce a state of hypovolaemic shock linked to inflammation and a capillary leak syndrome, responsible for the formation of a voluminous third sector. Initial resuscitation of burn patients is based on an assessment of filling requirements using the Parkland formula, which takes into account the patient's weight and the percentage of burned skin surface. This haemodynamic resuscitation oscillates between a risk of underfilling, responsible for hypovolaemia with low cardiac output and leading to excess mortality, and a state of hydric hyperinflation responsible for numerous complications such as respiratory distress, cardiac failure, abdominal compartment syndrome, and even excess mortality. The necessary adaptation of vascular filling rates is usually achieved by monitoring clinical parameters such as diuresis, or biological parameters such as arterial lactate or haematocrit. More advanced haemodynamic monitoring may be applied in addition, but the targets chosen and their numerical objectives remain to be validated. Due to the burn-induced capillary leak syndrome, quantification of extracellular (intra- and extravascular) fluid volume (ECFV) could be a relevant marker of fluid overload status in severely burned patients. ECFV can be estimated using intravenous glucose. Glucose is distributed throughout the extracellular fluid compartment within a few minutes, and defines an initial volume of glucose distribution (IDVG) proportional to the ECFV. This measurement has been validated in healthy individuals and in various pathological conditions. In intensive care patients, the values are between 3.1 and 4.8 L/m2.

To the best of our knowledge, no study has assessed variations in ECV measured by the LVDI in severely burned patients in the early phase of intensive care. Understanding these variations could make a definite contribution to the adaptation of perfused fluid volumes.
Since 1992, transabdominal LA(laparoscopic adrenalectomy) has been a standard method of adrenalectomy. This traditional method has been used widely because this procedure provides wide view of the whole abdomen which is familiar to surgeons. But due to its unique location at retroperitoneum, adrenal is still not easy to approach. So various retroperitoneal approaches were designed and adjusted. Among those, PRA(posterior retroperitoneal adrenalectomy) has showed good outcomes in many institutes. PRA facilitates direct approach to kidney and adrenal gland, and so operative time can be shortened. But there has been no randomized controlled trial between these two methods.

Therefore, as experienced surgeons in both methods, we want to practice this study.
Adolescent females who completed their last dose of domestic bivalent HPV vaccine or imported HPV vaccine and were between 13 and 14 years of age at the time of the first dose. Two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of vaccination.
1337140 Pressure sensitive record sheets FUJI PHOTO FILM CO Ltd 30 Sept 1971 [2 Oct 1970 27 Oct 1970 10 Nov 1970 (2) 30 Nov 1970 15 Dec 1970] 45664/71 Heading D2B [Also in Division B2] A capsule-coated sheet comprises a plastics film support having coated thereon a capsule layer, the plastics film having been subjected to at least one of the following treatments. (1) Corona discharge treatment, (2) flame treatment, (3) coating with a synthetic resin emulsion, (4) treatment by a liquid capable of swelling the plastics film or a mixture of such a liquid and a liquid not capable of swelling the film, and (5) coating with a fine granular solid material, before the application of the capsule layer, to reduce the contact angle of the surface of the film to less than 75‹. The synthetic resin emulsion in (3) may be emulsions of a vinyl acetate homopolymer, a vinyl chloride homopolymer, a vinylidene chloride homopolymer, an acrylic homopolymer, a styrene homopolymer, an ethylenic homopolymer, a butadiene homopolymer, an epoxy homopolymer, an amide homopolymer, a silicone homopolymer and copolymers thereof. Examples of the combinations of the plastics film and the swelling liquid are given. After treatment with the swelling liquid the plastics film may be treated with a non-swelling agent to coagulate the swelled surface portion to form a mat surface. Examples of the granular materials in (5) are given. They may be applied by coating or spraying a dispersion thereof in a swelling liquid for the plastics film, by coating on the plastics film a mixture of the granular material, a synthetic resin binder, and an organic solvent for the binder, or by coating on the film a mixture of the solid particles, and a hydrophilic polymer or a synthetic resin emulsion. The plastics films may be polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyester, polyamide, polycarbonate or cellulose acetate. The preferred films are biaxially orientated. The capsules may be produced by (a) coacervation process from aqueous solution, (b) interfacial polymerisation, (c) polymerisation of monomer in oily droplets, (d) liquifying, dispersing and cooling waxy material, (e) spray drying, or (f) internal accumulation. In a typical Example a coacervate comprising a liquid membrane of gelatin and gum arabic formed around oily droplets containing crystal violet lactone was cooled to gel the liquid membrane and the wall mem branes hardened by adding formaldehyde solution, then aqueous sodium carboxymethyl cellulose and aqueous caustic soda. The temperature was then raised to 50‹C. and cellulose flock added to obtain a capsule liquid. Biaxially oriented polystyrene film was subjected to flame treatment to impart a contact angle of 45‹ thereto, and the support coated with the capsule liquid and dried to obtain a colourformer sheet for pressure-sensitive recording paper.
[GB1337140A]
When adult patients on hemodialysis are given the recommended daily dose of 500 mg of Ertapenem for injection within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If Ertapenem for injection is given at least 6 hours prior to hemodialysis, no supplementary dose is needed. There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis.   
When only the serum creatinine is available, the following formula 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function.
SCOPE: Vitexin, a C-glycosylated flavonoid, is abundant in food sources and has potential health-beneficial properties. However, the targets for its beneficial effects remain largely unknown. This study aims to establish an in vitro cell model of vascular low-grade inflammation and explore the antiinflammatory mechanism of vitexin.
METHODS AND RESULTS: Low-dose TNFα and IL-17 are combined to establish a cell model of vascular low-grade inflammation. Cell-based studies show that low-dose TNFα (1 ng mL-1) alone has a slight effect, but its combination with IL-17 can potently induce protein expression of inflammatory cytokines, leading to an inflammatory state. However, the vascular inflammation caused by low-dose TNF plus IL-17 does not lead to oxidative stress, and reactive oxygen species (ROS) does not involved in developing this inflammation. Vitexin can be absorbed by human umbilical vein endothelial (HUVEC) cells to increase the Nrf2 protein level and attenuate inflammation. In addition, the antiinflammatory effect of vitexin is blocked by the knockdown of Nrf2. Further localized surface plasmon resonance, drug affinity responsive target stability, and molecular docking demonstrate that vitexin can directly interact with Keap1 to disrupt Keap1-Nrf2 interaction and thus activate Nrf2. Treatment of mice with a bolus oral gavage of vitexin (100 mg kg-1 body weight) or a high-fat diet supplemented with vitexin (5 mg kg-1 body weight per day) for 12 weeks confirms the rapid increase in blood vitexin levels and subsequent incorporation into blood vessels to activate Nrf2 and ameliorate inflammation in vivo.
CONCLUSION: The findings provide a reliable cell model of vascular low-grade inflammation and indicate Nrf2 protein as the potential target of vitexin to inhibit vascular inflammation.
Nationally, around 2,150 new cases of cancer are diagnosed per year in children aged 0 to 18. The main locations are leukemia, central system tumors and lymphomas. The onco-pediatrics unit of the Poitiers University Hospital is recruiting around 70 patients per year from 0 to under 18 years old. 1482 invasive procedures have been done in 2019. The diagnostic and therapeutic methods for these children remain aggressive and involve patients in chronic care. They repeatedly undergo painful and anxiety-inducing care. In pediatrics, nitrous oxide is chosen as the first-line choice in these various procedures, but its effectiveness is not always conclusive, due to habituation, and can induce side effects. For some children, it becomes difficult to obtain their consent to care, despite the range of different analgesics offered, and forces prescribers to increase the drugs. Virtual reality (VR) has already been shown to be effective on pain and anxiety in children and adolescents. This devices uses distraction and hypnosis techniques by establishing a state of hypnosedation and mediation through the work of breathing and sophrology. With this study, we expect the same benefit by using VR as usual pratices.

After explaining the treatment protocol, the potentially eligible patient will be informed by the investigator of the possibility of participating in this clinical trial. After checking the eligibility criteria and including the patient, the investigator can randomize the patient in the control group or the experimental group. As part of this study, patients will be followed for 1 month and for each act of lumbar puncture and connection to an implantable chamber.
This is a 2-year controlled, double-blind, randomized Phase 2 clinical trial comparing the efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. The scientific premise of the clinical trial is that circulating concentrations of vitamin D3, the parent compound, are the principal determinant of the anti-infective and immunomodulatory effects of supplementation.

Eligible participants will be initially screened to determine their blood vitamin D levels. Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be assigned by chance to one of the two arms for 24 months. Participants will be checked every month and will have periodic blood and urine tests to monitor for any side effects of the study treatments. Children above 5 y/o who can cooperate and understand the procedure will have lung function test at baseline and at 24 months. Showing that a monthly dose of vitamin D reduces lung infections, asthma and the acute chest syndrome could help establish this simple, low-cost treatment as a way to decrease sickness and deaths in children and adolescents with sickle-cell disease.